Prior Auth Required
02110 - Vyvgart (efgartigimod) Prescribing information, Argenx US, Inc., Boston, MA . Revised 12/2021. 8/2024 8/2024
This procedure appears on the selected insurer prior authorization source.
Prior authorizationPrior Auth Required
Procedure / ServiceVyvgart (efgartigimod) Prescribing information, Argenx US, Inc., Boston, MA . Revised 12/2021. 8/2024 8/2024
Procedure / Service Description
Updated Accessed - ICER. Eculizumab and Efgartigimod for the Treatment of Myasthenia Gravis: Effectiveness and Value. Final 10/2021 1/2022 Report, Report-at-a-Glance, Key Policy Recommendations. Evidence Report. 2021 Oct 20. Vyvgart (efgartigimod) Prescribing information, Argenx US, Inc., Boston, MA 02110. Revised 12/2021. 8/2024 8/2024 Reviewed 1/2022 Vyvgart (efgartigimod) Clinical Trial ADAPT (NCT03669588) Available at: 3/2021 1/2022
Likely documents
- Confirm benefit details
- Submit clinical notes if requested by the plan
Next actions
- Confirm the current plan policy before submission.
- Use the insurer authorization workflow for this listed code.